SGI
LAB icon

Summit Global Investments’s Standard BioTools LAB Stock Holding History

Summit Global Investments’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-78,700
Closed -$356K – 594
2021
Q1 		$356K Buy
+78,700
New +$432K 0.02% 426

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Summit Global Investments's LAB Position: Q2 2021 in Review

Summit Global Investments sold out of Standard BioTools (LAB) in Q2 2021, closing a stake of 78,700 shares — an estimated $356K sold.

Summit Global Investments first reported a position in LAB in Q1 2021 and held it in 1 quarter. The position peaked at $356K in Q1 2021. 113 funds tracked by Wall St. Rank hold LAB as of Q2 2021.

  • Summit Global Investments reported no remaining Standard BioTools position as of Q2 2021 after selling out during the quarter.
  • Summit Global Investments sold 78,700 Standard BioTools shares in Q2 2021, an estimated $356K.
  • Summit Global Investments first reported a position in Standard BioTools in Q1 2021 and held it in 1 quarter.
  • Summit Global Investments's Standard BioTools position peaked at $356K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2021.

Based on Summit Global Investments's 13F filing for Q2 2021, filed 28 Jan 2022.